Free Trial

Allspring Global Investments Holdings LLC Buys 29,465 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Tarsus Pharmaceuticals logo with Medical background

Allspring Global Investments Holdings LLC grew its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 16.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 210,531 shares of the company's stock after purchasing an additional 29,465 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.56% of Tarsus Pharmaceuticals worth $6,924,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in TARS. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $114,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after purchasing an additional 1,530 shares during the period. Dark Forest Capital Management LP acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $202,000. Finally, Bleakley Financial Group LLC acquired a new stake in Tarsus Pharmaceuticals during the 1st quarter worth $223,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TARS. Oppenheimer reaffirmed an "outperform" rating and set a $63.00 price objective (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals has an average rating of "Buy" and an average price target of $51.60.

Check Out Our Latest Analysis on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Stock Up 0.7 %

TARS stock traded up $0.26 during trading hours on Monday, reaching $39.67. 591,344 shares of the stock were exchanged, compared to its average volume of 700,149. The firm's 50-day moving average is $32.16 and its 200-day moving average is $31.21. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -8.79 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99. Tarsus Pharmaceuticals, Inc. has a 12 month low of $13.69 and a 12 month high of $42.50.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.98) by $0.10. The firm had revenue of $40.81 million during the quarter, compared to analysts' expectations of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same quarter in the prior year, the company earned ($1.17) EPS. On average, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.71 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

(Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Articles

Institutional Ownership by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

Should you invest $1,000 in Tarsus Pharmaceuticals right now?

Before you consider Tarsus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.

While Tarsus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines